All 20 eyes of the 10 male patients in our study cohort were affected by XLRS bilaterally. The average age of these patients was 17.6 years (range, 6–30 years), and the average refractive error was 0.71 D (range, −4.25 to 7.25). The individual clinical and OCT characteristics of these patients are listed in
Table 1. Of the 20 eyes under study, foveoschisis and peripheral retinoschisis were observed in 17 eyes (85%) and 11 eyes (55%), respectively. Three eyes (15%) showed peripheral retinoschisis without foveal extension, and nine eyes (45%) showed only foveoschisis without peripheral extension. Defects in photoreceptor microstructures were detected in 15 eyes (75%), showing an occurrence similar to that of schisis of the inner retinal layer (17 eyes; 85%). Defects in photoreceptor microstructures were present only in eyes with foveoschisis. When the clinical and tomographic data of the patients were compared with those for the control group, BCVA, CST, inferior and nasal choroidal thickness, and PROS lengths showed significant differences between the two groups (
Table 2). The average subfoveal choroidal thickness was approximately 35 μm thicker in the patient group, but it failed to achieve statistical significance (
P = 0.084). Foveoschisis in the INL and OPL and shortened PROS lengths with defects in the ELM, IS/OS junction, and COST line were observed dominantly compared with the matched control eyes (
Fig.). Outer plexiform layer schisis was observed frequently (60%) as multiple hyposignal isolated or connected spaces between the hypersignal double-layered OPL in the affected group (Figs. A, B, D). Regarding the manual measurements of choroidal thickness and PROS length, the interobserver agreements were good: The ICCs based on the whole cohort in the subfoveal, nasal, temporal, and superior and inferior choroidal thickness and PROS length measurements were 0.936, 0.905, 0.895, 0.884, 0.891, and 0.916, respectively. The ICCs of each group also revealed good interobserver reliability of the measurements (
Table 3).